Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication

被引：4

作者：

Shimony, Shai ^{[1
,2
]}

Mintz, Hilla Reiss ^{[3
]}

Beryozkin, Yulia Shvartser ^{[4
]}

Shoham, Avivit ^{[5
]}

Raanani, Pia ^{[1
,2
]}

Wolach, Ofir ^{[1
,2
]}

机构：

[1] Beilinson Med Ctr, Davidoff Canc Ctr, Inst Hematol, Rabin Med Ctr, Petah Tiqwa, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Beilinson Med Ctr, Div Gastroenterol, Rabin Med Ctr, Petah Tiqwa, Israel

[4] Beilinson Med Ctr, Div Pathol, Rabin Med Ctr, Petah Tiqwa, Israel

[5] Beilinson Med Ctr, Radiol Dept, Rabin Med Ctr, Petah Tiqwa, Israel

来源：

ACTA HAEMATOLOGICA | 2020年 / 143卷 / 01期

关键词：

Acute myeloid leukemia; Midostaurin; Hemorrhagic gastritis;

D O I：

10.1159/000500975

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Midostaurin is a tyrosine multikinase inhibitor approved for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with mutated Fms-like tyrosine kinase-3. We describe a case report of a 49-year-old AML patient treated with an intensive chemotherapy regimen followed by midostaurin. After achieving complete remission with blood count recovery, he suffered from a serious, rare complication of necrotizing hemorrhagic gastritis with no evidence of infection or malignant infiltration, possibly associated with midostaurin therapy.

引用

页码：65 / 68

页数：4

共 50 条

[11] Remission induction in acute myeloid leukemia
Stein, Eytan M.
Tallman, Martin S.
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (02) : 164 - 170
[12] Remission induction in acute myeloid leukemia
Eytan M. Stein
Martin S. Tallman
International Journal of Hematology, 2012, 96 : 164 - 170
[13] Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin
Perrone, Salvatore
Lisi, Chiara
La Barbera, Elettra Ortu
Luise, Cristina
Lichtner, Miriam
Girmenia, Corrado
Cimino, Giuseppe
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
[14] Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use
Abdul-Hamil, Nurul A.
Wong, Gee C.
Nagarajan, Chandramouli
Martinelli, Giovanni
Cherchione, Claudio
MINERVA MEDICA, 2020, 111 (05) : 443 - 454
[15] Necrotizing fasciitis of the vulva due to carbapenem-resistant Enterobacteriaceae as a complication of acute myeloid leukemia treatment: a case report
Marta Leal Bento
Leonor Vasconcelos de Matos
Lídia Alves Ribeiro
Olavo Gomes
Filipa Nogueira
Graça Esteves
Sara Valle
Helena Martins
João Raposo
Journal of Medical Case Reports, 16
[16] Necrotizing fasciitis of the vulva due to carbapenem-resistant Enterobacteriaceae as a complication of acute myeloid leukemia treatment: a case report
Bento, Marta Leal
de Matos, Leonor Vasconcelos
Ribeiro, Lidia Alves
Gomes, Olavo
Nogueira, Filipa
Esteves, Graca
Valle, Sara
Martins, Helena
Raposo, Joao
JOURNAL OF MEDICAL CASE REPORTS, 2022, 16 (01)
[17] Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Gallogly, Molly M.
Lazarus, Hillard M.
Cooper, Brenda W.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (09) : 245 - 261
[18] New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia
Mattison, Ryan J.
Luger, Selina M.
Lazarus, Hillard M.
CURRENT OPINION IN HEMATOLOGY, 2013, 20 (02) : 93 - 99
[19] Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive
Garcia, J. S.
Percival, M. E.
DRUGS OF TODAY, 2017, 53 (10) : 531 - 543
[20] Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Sonia Jaramillo
Richard F. Schlenk
Current Oncology Reports, 2021, 23

← 1 2 3 4 5 →